AMARIN CORP PLC\UK
AMRNDrugs in Pipeline
4
Phase 3 Programs
4
Upcoming Catalysts
1
Next Catalyst
Jul 29, 2026
6dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
AMRN Earnings Report
EPS Est: $-0.21 | FQ end 2026-06
Ethyl-EPA (Miraxion™)
Huntington Disease
AMR101 (ethyl icosapentate) - 4 g/day
Hypertriglyceridemia
AMR101 (ethyl icosapentate) - 2 g/day
Hypertriglyceridemia
AMR101
Cardiovascular Diseases
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Ethyl-EPA (Miraxion™) | Phase 3 | Huntington Disease | - | - |
AMR101 (ethyl icosapentate) - 4 g/day | Phase 3 | Hypertriglyceridemia | - | - |
AMR101 (ethyl icosapentate) - 2 g/day | Phase 3 | Hypertriglyceridemia | - | - |
AMR101 | Phase 3 | Cardiovascular Diseases | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in AMARIN CORP PLC\UK's drug pipeline?→
CatalystAlert tracks 4 drug candidates in AMARIN CORP PLC\UK's (AMRN) pipeline across Phase 3. Its lead program is Ethyl-EPA (Miraxion™) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is AMARIN CORP PLC\UK's next FDA catalyst?→
AMARIN CORP PLC\UK's (AMRN) next tracked catalyst is a Earnings expected July 29, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track AMRN biotech catalysts?→
Add AMRN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow AMARIN CORP PLC\UK's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.